Vaping Versus Smoking: a quest for Efficacy and Safety of E-cigarette

Introduction:
This text provides an analysis of the regulatory status of electronic cigarettes (ECIGs) across the globe, with a focus on the United States, the United Kingdom, and India. The reader will learn about the different regulatory approaches taken by these countries and the implications of these policies for public health.

Key Points:

* In the United States, ECIGs are classified as tobacco products and are subject to the same regulations as traditional cigarettes. This includes a ban on sales to individuals under 18 years of age and the requirement for companies to disclose ingredients and undergo approval.
* In the United Kingdom, ECIGs can be marketed as medicines or as consumer products. Seeking approval for ECIGs as medicinal products requires undergoing the standard licensing process, while approval for consumer products requires standardizing the manufacturing process, disclosing full ingredients, using child-proof packaging, and prohibiting television commercials.
* In India, ECIGs are not regulated as tobacco products or as nicotine replacement therapy (NRT) products. however, the CDSCO has approved nicotine-containing chewing gums, lozenges, and inhalers for NRT. The lack of regulations in most states of India poses a serious threat of its abuse by adults, teenagers, and even children.
* The Union health Ministry of India has formed a working group to assess the gradually expanding ECIG market and its implications on the Indian population.

Main Message:
The regulatory status of ECIGs varies widely across countries, with some countries taking a more proactive approach to regulating these products while others have yet to establish clear guidelines. Given the potential risks associated with ECIG use, it is crucial for countries to establish clear and effective regulations to protect public health. In India, where the market for ECIGs is expanding rapidly, it is essential for the government to take action to regulate these products to reduce tobacco-related mortality and morbidity.

Rehan, harmeet Singh, Jahnavi Maini, and amrit Pal Singh hungin. “Vaping Versus Smoking: a quest for Efficacy and Safety of E-Cigarette.” Current Drug Safety 13, no. 2 (June 12, 2018): 92–101. https://doi.org/10.2174/1574886313666180227110556.